Neurovance

company

About

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$7M
Industries
Biotechnology,Clinical Trials,Health Care,Neuroscience
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Close

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

Neurovance has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB), and Timothy J. Barberich.

It was founded in 2009 and is headquartered in Cambridge, Massachusetts.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$13.30M
Neurovance has raised a total of $13.30M in funding over 2 rounds. Their latest funding was raised on Apr 3, 2014 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 3, 2014 Series A $6.30M 1 Detail
Oct 18, 2012 Series Unknown $7M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Neurovance is funded by 1 investors. H&Q Healthcare Investors are the most recent investors.
Investor Name Lead Investor Funding Round
H&Q Healthcare Investors Series A